ইউরোপীয় ইউনিয়ন - মল্টিয় - EMA (European Medicines Agency)

hexal ag - temozolomide - glioma; glioblastoma - aġenti antineoplastiċi - għat-trattament ta 'pazjenti adulti b'glioblastoma multiforme dijanjostikata fl-istess ħin ma' radjuterapija (rt) u sussegwentement bħala trattament b'monoterapija. għall-kura tat-tfal mill-età ta ' tliet snin fuq, adolexxenti, u pazjenti adulti bi glijoma malinna, bħal glioblastoma multiforme jew astroċitoma anaplastika, li jerġgħu jirkadu jew progressjoni wara terapija standard.

ইউরোপীয় ইউনিয়ন - মল্টিয় - EMA (European Medicines Agency)

novo nordisk a/s - insulin human - diabetes mellitus - drogi użati fid-dijabete - trattament tad-dijabete mellitus.

ইউরোপীয় ইউনিয়ন - মল্টিয় - EMA (European Medicines Agency)

bayer ag - radium (223ra) dichloride - neoplasmi prostatiċi - radjofarmaċewtiċi terapewtiċi - xofigo huwa indikat għat-trattament ta 'adulti b'kanċer tal-prostata li jiflaħ għall-kastrazzjoni, metastasi sintomatika fl-għadam u l-ebda metastasi viscerali magħrufa.

ইউরোপীয় ইউনিয়ন - মল্টিয় - EMA (European Medicines Agency)

bayer ag - damoctocog alfa pegol - hemofilja a - sustanzi kontra l-emorraġija - kura u profilassi ta ' fsada f'pazjenti li kienu kkurati qabel ≥ 12-il sena bl-emofilja a (nuqqas konġenitali tal-fattur viii).

ইউরোপীয় ইউনিয়ন - মল্টিয় - EMA (European Medicines Agency)

bayer ag - larotrectinib sulfat - addominali neoplażmi - aġenti antineoplastiċi - vitrakvi bħala monoterapija hija indikata għat-trattament ta 'pazjenti adulti u pedjatriċi b'tumuri solidi li juru neurotrophic tyrosine tar-riċettur tal-kinase (ntrk) tal-ġene tal-fużjoni,li jkollhom mard li huwa lokalment avvanzat, metastatiku jew fejn il-risezzjoni kirurġika huwa probabbli li jirriżulta f'sever tal-morbidità, andwho jkollhom l-ebda sodisfaċenti għażliet ta' trattament.

ইউরোপীয় ইউনিয়ন - মল্টিয় - EMA (European Medicines Agency)

stada arzneimittel ag - bevacizumab - colorectal neoplasms; breast neoplasms; ovarian neoplasms; fallopian tube neoplasms; peritoneal neoplasms; carcinoma, non-small-cell lung; carcinoma, renal cell; uterine cervical neoplasms - aġenti antineoplastiċi - oyavas in combination with fluoropyrimidine based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum. oyavas in combination with paclitaxel is indicated for first line treatment of adult patients with metastatic breast cancer. għal aktar informazzjoni dwar l-istatus tal-fattur tat-tkabbir tal-epidermide tal-bniedem 2 (her2), jekk jogħġbok irreferi għat-taqsima 5. oyavas in combination with capecitabine is indicated for first line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. patients who have received taxane and anthracycline containing regimens in the adjuvant setting within the last 12 months should be excluded from treatment with oyavas in combination with capecitabine. għal aktar informazzjoni dwar l-istatus ta 'her2, jekk jogħġbok irreferi għat-taqsima 5. oyavas, in addition to platinum based chemotherapy, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent non small cell lung cancer other than predominantly squamous cell histology. oyavas, in combination with erlotinib, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent non squamous non small cell lung cancer with epidermal growth factor receptor (egfr) activating mutations (see section 5. oyavas in combination with interferon alfa 2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer. oyavas, in combination with carboplatin and paclitaxel is indicated for the front line treatment of adult patients with advanced (international federation of gynecology and obstetrics (figo) stages iii b, iii c and iv) epithelial ovarian, fallopian tube, or primary peritoneal cancer (see section 5. oyavas, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor–targeted agents. oyavas, in combination with topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor targeted agents (see section 5. oyavas, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix (see section 5.

ইউরোপীয় ইউনিয়ন - মল্টিয় - EMA (European Medicines Agency)

bayer ag - vericiguat - insuffiċjenza tal-qalb - terapija kardijaka - treatment of symptomatic chronic heart failure.

ইউরোপীয় ইউনিয়ন - মল্টিয় - EMA (European Medicines Agency)

takeda pharmaceuticals international ag ireland branch - idursulfase - mucopolysaccharidosis ii - oħra tal-passaġġ alimentari u tal-metaboliżmu-prodotti, - elaprase huwa indikat għall-kura fit-tul ta ' pazjenti bl-kaċċatur syndrome (mucopolysaccharidosis ii, mps ii). in-nisa eterozigoti ma ġewx studjati fil-provi kliniċi.

ইউরোপীয় ইউনিয়ন - মল্টিয় - EMA (European Medicines Agency)

bayer ag - octocog alfa - hemofilja a - sustanzi kontra l-emorraġija - trattament u profilassi ta 'fsada f'pazjenti b'emofilja a (nuqqas konġenitali ta' fattur viii). kovaltry jista 'jintuża għall-etajiet kollha.

ইউরোপীয় ইউনিয়ন - মল্টিয় - EMA (European Medicines Agency)

bayer ag - sorafenib - carcinoma, hepatocellular; carcinoma, renal cell - aġenti antineoplastiċi - epatoċellulari carcinomanexavar huwa indikat għall-kura ta ' karċinoma epatoċellulari. taċ-ċelluli renali carcinomanexavar huwa indikat għall-kura ta ' pazjenti b'karċinoma taċ-ċellola renali li kellhom falliment ta qabel l-interferon-alpha jew interleukin-2 ibbażat fuq it-terapija jew li huma ikkunsidrati mhux tajba għal terapija bħal din. tat-tirojde differenzjat carcinomanexavar huwa indikat għall-kura ta ' pazjenti b'progressiva, lokalment avvanzat jew dak metastatiku, differenzjati (papillari/follikulari/hürthle taċ-ċelluli) karċinoma tat-tirojde, refrattarji għat-jodju radjuattiv.